TY - JOUR
T1 - Traction of 3D and 4D printing in the healthcare industry, from drug discovery and analysis to regenerative medicine
AU - Osouli-Bostanabad, Karim
AU - Masalehdan, Tahereh
AU - Kapsa, Robert M. I.
AU - Quigley, Anita
AU - Lalatsa, Katerina
AU - Bruggeman, Kiara F.
AU - Franks, Stephanie J.
AU - Williams, Richard J.
AU - Nisbet, David
PY - 2022/7/11
Y1 - 2022/7/11
N2 - Three-dimensional (3D) printing and 3D bioprinting are promising technologies for a broad range of healthcare applications, from frontier regenerative medicine and tissue engineering therapies through to pharmaceutical advancements, yet must overcome the challenges of biocompatibility and resolution. Through comparison of traditional biofabrication methods with 3D (bio)printing, this review highlights the promise of 3D printing for the production of on-demand, personalized and complex products that enhance the accessibility, effectiveness, and safety of drug therapies and delivery systems. In addition, this review describes the capacity of 3D bioprinting to fabricate patient-specific tissues and living cell systems (e.g. vascular networks, organs, muscles, and skeletal systems), as well as its applications in delivery of cells and genes, microfluidics and organon- chip constructs. This review summarises how tailoring selected parameters (i.e. accurately selecting appropriate printing method, materials and printing parameters based on the desired application and behavior) can better facilitate the development of optimised 3D-printed products, and how dynamic 4D-printed strategies (printing materials designed to change with time or stimulus) may be deployed to overcome many of the inherent limitations of conventional 3Dprinted technologies. Comprehensive insights into a critical perspective of the future of 4D bioprinting, crucial requirements for 4D printing including programmability of a material, multimaterial printing methods, and precise designs for meticulous transformations or even clinical applications are also given.
AB - Three-dimensional (3D) printing and 3D bioprinting are promising technologies for a broad range of healthcare applications, from frontier regenerative medicine and tissue engineering therapies through to pharmaceutical advancements, yet must overcome the challenges of biocompatibility and resolution. Through comparison of traditional biofabrication methods with 3D (bio)printing, this review highlights the promise of 3D printing for the production of on-demand, personalized and complex products that enhance the accessibility, effectiveness, and safety of drug therapies and delivery systems. In addition, this review describes the capacity of 3D bioprinting to fabricate patient-specific tissues and living cell systems (e.g. vascular networks, organs, muscles, and skeletal systems), as well as its applications in delivery of cells and genes, microfluidics and organon- chip constructs. This review summarises how tailoring selected parameters (i.e. accurately selecting appropriate printing method, materials and printing parameters based on the desired application and behavior) can better facilitate the development of optimised 3D-printed products, and how dynamic 4D-printed strategies (printing materials designed to change with time or stimulus) may be deployed to overcome many of the inherent limitations of conventional 3Dprinted technologies. Comprehensive insights into a critical perspective of the future of 4D bioprinting, crucial requirements for 4D printing including programmability of a material, multimaterial printing methods, and precise designs for meticulous transformations or even clinical applications are also given.
KW - bioprinting
KW - 3D-printed technology
KW - 4D-printing technology
KW - microfluidics
U2 - 10.1021/acsbiomaterials.2c00094
DO - 10.1021/acsbiomaterials.2c00094
M3 - Literature review
SN - 2373-9878
VL - 8
SP - 2764
EP - 2797
JO - ACS Biomaterials Science and Engineering
JF - ACS Biomaterials Science and Engineering
IS - 7
ER -